AZN
Income statement / Annual
Last year (2024), AstraZeneca PLC's total revenue was $54.07 B,
an increase of 18.03% from the previous year.
In 2024, AstraZeneca PLC's net income was $7.04 B.
See AstraZeneca PLC,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$54.07 B |
$45.81 B |
$44.35 B |
$37.42 B |
$26.62 B |
$24.38 B |
$22.09 B |
$22.47 B |
$23.00 B |
$24.71 B |
Cost of Revenue |
$10.21 B
|
$8.04 B
|
$12.39 B
|
$12.44 B
|
$5.30 B
|
$4.92 B
|
$4.94 B
|
$4.32 B
|
$4.13 B
|
$4.65 B
|
Gross Profit |
$43.87 B
|
$37.77 B
|
$31.96 B
|
$24.98 B
|
$21.32 B
|
$19.46 B
|
$17.15 B
|
$18.15 B
|
$18.88 B
|
$20.06 B
|
Gross Profit Ratio |
0.81
|
0.82
|
0.72
|
0.67
|
0.8
|
0.8
|
0.78
|
0.81
|
0.82
|
0.81
|
Research and Development Expenses |
$13.58 B
|
$10.94 B
|
$9.76 B
|
$9.74 B
|
$5.99 B
|
$5.96 B
|
$5.93 B
|
$5.76 B
|
$5.89 B
|
$6.00 B
|
General & Administrative Expenses |
$19.98 B
|
$19.22 B
|
$0.00
|
$0.00
|
$0.00
|
$11.68 B
|
$0.00
|
$10.23 B
|
$9.41 B
|
$11.11 B
|
Selling & Marketing Expenses |
$555.00 M
|
$539.00 M
|
$18.96 B
|
$15.68 B
|
$11.69 B
|
$11.85 B
|
$10.36 B
|
$10.54 B
|
$9.74 B
|
$11.45 B
|
Selling, General & Administrative Expenses |
$20.53 B
|
$18.03 B
|
$18.96 B
|
$15.68 B
|
$11.69 B
|
$11.85 B
|
$10.36 B
|
$10.54 B
|
$9.74 B
|
$11.45 B
|
Other Expenses |
-$252.00 M
|
$618.00 M
|
-$514.00 M
|
-$1.49 B
|
-$1.53 B
|
-$1.54 B
|
-$650.00 M
|
-$10.44 B
|
-$9.74 B
|
-$11.63 B
|
Operating Expenses |
$33.86 B
|
$29.58 B
|
$28.20 B
|
$23.92 B
|
$16.16 B
|
$16.27 B
|
$13.77 B
|
$14.47 B
|
$13.97 B
|
$15.95 B
|
Cost And Expenses |
$44.07 B
|
$37.62 B
|
$40.59 B
|
$36.36 B
|
$21.46 B
|
$21.19 B
|
$18.70 B
|
$18.79 B
|
$18.10 B
|
$20.59 B
|
Interest Income |
$458.00 M
|
$291.00 M
|
$95.00 M
|
$43.00 M
|
$87.00 M
|
$172.00 M
|
$138.00 M
|
$113.00 M
|
$67.00 M
|
$46.00 M
|
Interest Expense |
$1.74 B
|
$1.59 B
|
$1.35 B
|
$1.30 B
|
$1.31 B
|
$1.43 B
|
$1.42 B
|
$1.51 B
|
$1.38 B
|
$1.08 B
|
Depreciation & Amortization |
$6.69 B
|
$5.39 B
|
$5.25 B
|
$4.10 B
|
$2.90 B
|
$3.76 B
|
$3.75 B
|
$3.04 B
|
$2.36 B
|
$2.85 B
|
EBITDA |
$17.12 B |
$13.42 B |
$9.09 B |
$5.11 B |
$8.08 B |
$6.71 B |
$7.11 B |
$6.62 B |
$7.28 B |
$6.96 B |
EBITDA Ratio |
0.32
|
0.29
|
0.21
|
0.2
|
0.31
|
0.29
|
0.32
|
0.3
|
0.32
|
0.28
|
Operating Income Ratio |
0.18
|
0.18
|
0.08
|
0.03
|
0.19
|
0.12
|
0.15
|
0.16
|
0.21
|
0.17
|
Total Other Income/Expenses Net |
-$1.31 B
|
-$1.29 B
|
-$1.26 B
|
-$1.32 B
|
-$1.25 B
|
-$1.38 B
|
-$1.39 B
|
-$1.45 B
|
-$1.35 B
|
-$1.05 B
|
Income Before Tax |
$8.69 B
|
$6.90 B
|
$2.50 B
|
-$265.00 M
|
$3.92 B
|
$1.55 B
|
$1.99 B
|
$2.23 B
|
$3.55 B
|
$3.07 B
|
Income Before Tax Ratio |
0.16
|
0.15
|
0.06
|
-0.01
|
0.15
|
0.06
|
0.09
|
0.1
|
0.15
|
0.12
|
Income Tax Expense |
$1.65 B
|
$938.00 M
|
-$792.00 M
|
-$380.00 M
|
$772.00 M
|
$321.00 M
|
-$57.00 M
|
-$641.00 M
|
$146.00 M
|
$243.00 M
|
Net Income |
$7.04 B
|
$5.96 B
|
$3.29 B
|
$112.00 M
|
$3.20 B
|
$1.34 B
|
$2.16 B
|
$3.00 B
|
$3.50 B
|
$2.83 B
|
Net Income Ratio |
0.13
|
0.13
|
0.07
|
0
|
0.12
|
0.05
|
0.1
|
0.13
|
0.15
|
0.11
|
EPS |
2.27 |
1.92 |
2.12 |
0.08 |
2.44 |
1.03 |
1.7 |
2.37 |
2.77 |
2.23 |
EPS Diluted |
3 |
1.91 |
2.11 |
0.08 |
2.44 |
1.03 |
1.7 |
2.37 |
2.76 |
2.23 |
Weighted Average Shares Out |
$3.10 B
|
$3.10 B
|
$1.55 B
|
$1.42 B
|
$1.31 B
|
$1.30 B
|
$1.27 B
|
$1.27 B
|
$1.27 B
|
$1.26 B
|
Weighted Average Shares Out Diluted |
$2.34 B
|
$3.12 B
|
$1.56 B
|
$1.43 B
|
$1.31 B
|
$1.30 B
|
$1.27 B
|
$1.27 B
|
$1.27 B
|
$1.27 B
|
Link |
|
|
|
|
|
|
|
|
|
|